Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$366.4MCash on Hand
26.9mo Cash Runway
Follow SDGR by emailGet an email when SDGR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SDGR, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 4, 2026 ·
Earnings Reported Q3 2026 ACV of $44.7 million, up 17%, and drug discovery revenue of $24.2 million, boosted by a Structure Therapeutics milestone. Raised full-year 2026 ACV guidance to $222 million to $232 million and drug discovery revenue guidance to $75 million to $85 million. Form 8-K · SEC filing · Press release
Nov 4, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
SDGR holds $366.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $40.8M/quarter from operations,
an estimated runway of 26.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:25 · Moderate
Cash runway 27 months
ATM program on file since Feb 2024 +15
Shelf registration (S-3ASR, Feb 2024) +10
Recent financing filings on SEC EDGAR:
Feb 28, 2024 · Shelf registration with ATM program, up to $250M · S-3ASR
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SDGR and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.